RESUMEN
Recombinant human growth hormone (GH) therapy has been shown to be effective in the treatment of growth failure related to growth hormone resistance among children with chronic renal failure. The traditional route of administration is subcutaneous injection. This study was designed to evaluate the effectiveness and tolerability of intraperitoneal (i.p.) administration of GH in prepubertal peritoneal dialysis patients. Nine subjects were enrolled. Eight completed 24 months of therapy with GH. Baseline height standard deviation scores (SDS) and growth velocity for the prior year were used for comparison. Peak serum GH was achieved 4 h after administration and serum half-life was 4.6 h. Mean height SDS was -3.1 at baseline, -2.5 at 1 year, and -2.3 at 2 years (NS) of GH therapy. Mean height velocity increased from a baseline of 4.6 cm/yr to 8.5 cm/yr in year 1 (P < 0.05) and 6.1 cm/yr in year 2 (NS) of i.p. GH therapy. Peritonitis infection rates were not increased from overall center rates. This research suggests that the intraperitoneal route of administration of GH can be utilized in the treatment of short stature among children requiring maintenance peritoneal dialysis therapy.
Asunto(s)
Hormona de Crecimiento Humana/administración & dosificación , Fallo Renal Crónico/tratamiento farmacológico , Adolescente , Niño , Desarrollo Infantil , Preescolar , Femenino , Hormona de Crecimiento Humana/efectos adversos , Hormona de Crecimiento Humana/farmacocinética , Hormona de Crecimiento Humana/uso terapéutico , Humanos , Inyecciones Intraperitoneales , Fallo Renal Crónico/fisiopatología , Fallo Renal Crónico/terapia , Masculino , Estado Nutricional , Diálisis Peritoneal , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéutico , SeguridadRESUMEN
We performed 73 kidney transplants in 51 patients with steroid-resistant nephrotic syndrome (SRNS) with focal segmental glomerular sclerosis (FSG) ages 18.4 +/- 12.8 (mean +/- SD) years. Recurrence of SRNS, defined by rapid onset of proteinuria, hypoalbuminemia and/or > 95% epithelial cell foot process effacement with or without the presence of FSG, occurred in 26 grafts in 16 patients. Acute renal failure (ARF) occurred in 16 of 26 (61.5%) grafts with recurrence versus 7 of 47 (14.9%) grafts without recurrence (P < 0.0001). ARF occurred in 4 of 9 (44.4%) living-related donor (LRD) recipients with recurrence and 3 of 21 (12.5%) LRD recipients without recurrence (NS). ARF in cadaver donor (CAD) recipients with recurrence was 12 of 17 (70.5%) versus 4 of 23 (17.4%) without recurrence (P < 0.0001). ARF was also higher in LRD or CAD with recurrence than in a control group of non-SRNS patients matched for age, sex and time of transplantation. Graft survival at one year was lower in patients with recurrence and ARF [4 of 16 (25%)] compared to patients with recurrence and no ARF [9 of 11 (82%), P < 0.01]. There was no difference in graft survival in patients without recurrence who did or did not have ARF. One or more acute rejection episodes occurred in all 16 patients with ARF and recurrence, in all 7 patients with ARF without recurrence, and in 7 of 10 patients with recurrence without ARF compared with only 11 of 40 (28%) of patients with neither recurrence nor ARF (P < 0.0001, < 0.001 and < 0.04, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Lesión Renal Aguda/etiología , Glucocorticoides/uso terapéutico , Rechazo de Injerto/etiología , Trasplante de Riñón/efectos adversos , Síndrome Nefrótico/etiología , Adolescente , Resistencia a Medicamentos , Femenino , Glomeruloesclerosis Focal y Segmentaria/tratamiento farmacológico , Glomeruloesclerosis Focal y Segmentaria/etiología , Glomeruloesclerosis Focal y Segmentaria/cirugía , Supervivencia de Injerto , Humanos , Incidencia , Masculino , Síndrome Nefrótico/tratamiento farmacológico , Síndrome Nefrótico/cirugía , Recurrencia , Trasplante HomólogoRESUMEN
Acute serum sickness was induced in New Zealand White (NZW) and in C6 deficient (C6D) rabbits, to compare the histology, immunofluorescence, especially distribution of poly C9 (MAC), and electron microscopic characteristics of the disease in each strain. Glomerulonephritis and albuminuria of comparable extent occurred in 13/17 NZW and 4/8 C6D rabbits. In NZW rabbits with albuminuria an early intense glomerular infiltration by mononuclear cells was associated with focal small fine granular glomerular basement membrane (GBM) deposits of IgG and BSA and more diffuse and larger deposits of C3 and MAC. After the disappearance of monocytes and decrease in mesangial cell proliferation, development of large subepithelial GBM deposits rich in all immune reactants was observed in NZB rabbits. In C6D rabbits with albuminuria a similar monocytic infiltrate occurred, but no association with IgG and C3 GBM immune deposits was noted. No deposits of MAC and no large subepithelial GBM 'humps' were observed in C6D rabbits. We conclude that the exudative (monocytic) phase of glomerular injury and albuminuria in acute serum sickness nephritis are not dependent upon terminal complement components, but the subsequent formation of large subepithelial GBM deposits does not occur in this model in the absence of MAC.
Asunto(s)
Complemento C6/deficiencia , Complejo de Ataque a Membrana del Sistema Complemento/análisis , Enfermedad del Suero/patología , Albuminuria/etiología , Animales , Membrana Basal/ultraestructura , Complemento C3/análisis , Glomerulonefritis/etiología , Glomerulonefritis/patología , Inmunoglobulina G/análisis , Riñón/inmunología , Glomérulos Renales/ultraestructura , Masculino , Conejos , Albúmina Sérica Bovina/inmunología , Enfermedad del Suero/inmunologíaRESUMEN
Denys-Drash syndrome is a rare human condition in which severe urogenital aberrations result in renal failure, pseudohermaphroditism, and Wilms' tumor (nephroblastoma). To investigate its possible role, we have analyzed the coding exons of the Wilms' tumor suppressor gene (WT1) for germline mutations. In ten independent cases of Denys-Drash syndrome, point mutations in the zinc finger domains of one WT1 gene copy were found. Nine of these mutations are found within exon 9 (zinc finger III); the remaining mutation is in exon 8 (zinc finger II). These mutations directly affect DNA sequence recognition. In two families analyzed, the mutations were shown to arise de novo. Wilms' tumors from three individuals and one juvenile granulosa cell tumor demonstrate reduction to homozygosity for the mutated WT1 allele. Our results provide evidence of a direct role for WT1 in Denys-Drash syndrome and thus urogenital system development.
Asunto(s)
Proteínas de Unión al ADN/genética , Genes del Tumor de Wilms/genética , Mutación/genética , Anomalías Urogenitales , Dedos de Zinc/genética , Lesión Renal Aguda/genética , Secuencia de Aminoácidos , Secuencia de Bases , Línea Celular Transformada , Proteínas de Unión al ADN/metabolismo , Trastornos del Desarrollo Sexual/genética , Exones/genética , Femenino , Humanos , Datos de Secuencia Molecular , Mutagénesis , Fenotipo , Reacción en Cadena de la Polimerasa , Síndrome , Proteínas WT1 , Tumor de Wilms/genéticaRESUMEN
We analyzed the results obtained with protocols for immunosuppression of pediatric recipients of haploidentical living-related renal transplants. In the donor-specific transfusion group transfusion of blood products obtained from the prospective organ donor was performed before transplantation, and at transplantation maintenance immunosuppression of azathioprine and prednisone was begun. In the cyclosporine group donor-specific transfusion was not used, and maintenance immuno-suppression of cyclosporine and azathioprine was begun 1 week before transplantation, with the addition of prednisone at transplantation. Of 24 donor-specific transfusion recipients 3 had circulating cytotoxic antibodies to the prospective donor for an incidence of 12%. There was no significant difference between groups with respect to 1-year actual patient and graft survival (100 and 89 versus 100 and 86%, respectively), 1-year mean serum creatinine level (1.1 versus 1.2 mg./dl.), rejection treatments per patient (2.5 versus 2.6) and total days hospitalized during year 1 after transplantation (27 versus 18), with donor-specific transfusion data presented first. Initial hospitalization was significantly shorter (10 versus 16 days, p less than 0.05) and the incidence of rejection crises within 3 months was significantly less (68 versus 94%, p less than 0.05) in the cyclosporine group. We believe that cyclosporine and azathioprine pre-treatment of pediatric recipients of haploidentical living-related renal transplants with the addition of prednisone at transplantation is preferable to a donor-specific transfusion protocol because there is no risk of recipient sensitization to the prospective donor, and patient and graft survival is not adversely affected.
Asunto(s)
Transfusión Sanguínea/métodos , Ciclosporinas/uso terapéutico , Terapia de Inmunosupresión/métodos , Trasplante de Riñón/inmunología , Donantes de Tejidos , Azatioprina/uso terapéutico , Niño , Femenino , Rechazo de Injerto , Supervivencia de Injerto , Prueba de Histocompatibilidad , Humanos , Masculino , Prednisona/uso terapéuticoRESUMEN
Thirty-one pediatric patients with acute renal allograft rejection were treated with the monoclonal antibody OKT3. In 24 cases, increased doses of steroids followed by a polyclonal antithymocyte globulin were ineffective in reversing the rejection episode. Twenty-eight patients completed the prescribed minimum 10-day treatment course, with effective rejection reversal in 22. Three patients failed to complete the course of therapy: one because of leukopenia that developed after the first dose, one because of a clotted graft, and another because of symptomatic cytomegalovirus infection. The overall success rate of OKT3 for rejection reversal was 74%; however, 55% of recipients had rebound rejection, and 85% of patients had detectable anti-OKT3 antibodies after completion of the course of therapy. Ten patients were treated with a second course of OKT3, and in eight of these patients, rejection was at least temporarily reversed. The starting dose of OKT3 for second-course therapy was the same as that used during first-course therapy, but in five cases the dose was increased during the course because of inadequate therapeutic response. Seven of these patients lost their grafts a mean of 6.5 months after completion of second-course therapy. We looked for anti-OKT3 antibody in nine recipients after completion of a second treatment course and found it in all nine. Our observations regarding a second treatment course with this monoclonal antibody preparation suggest that although rejection reversal may be observed, ultimate graft survival is poor and anti-OKT3 antibody formation is enhanced.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Rechazo de Injerto/inmunología , Trasplante de Riñón/inmunología , Acetaminofén/uso terapéutico , Adolescente , Anticuerpos Antiidiotipos/análisis , Anticuerpos Monoclonales/administración & dosificación , Antígenos CD/análisis , Antígenos de Diferenciación de Linfocitos T/análisis , Suero Antilinfocítico/uso terapéutico , Azatioprina/uso terapéutico , Complejo CD3 , Niño , Preescolar , Difenhidramina/uso terapéutico , Humanos , Inmunoglobulina A , Lactante , Metilprednisolona/uso terapéutico , Prednisona/uso terapéutico , Receptores de Antígenos de Linfocitos T/análisis , Recurrencia , Linfocitos T/inmunologíaRESUMEN
Proteinuria may be an indication of underlying disease or may be found in various physiologic states. Careful quantitation of urinary protein and thorough patient evaluation are necessary to determine if proteinuria is cause for concern. Transient and orthostatic proteinuria appear to be benign, but persistent proteinuria may be a manifestation of serious disease.